Abstract
Real world evaluation of pathological complete response rates following the use of pembrolizumab alongside neo-adjuvant chemotherapy in early triple negative breast cancer
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the Royal College of Physicians of London
Paper Title
Journal
Date
